
About Acura Pharm
Acura Pharm is a publicly listed company based in Palatine (United States) founded in 1935. Abuse-deterrent drug delivery technologies are developed for medication safety. Acura Pharm offers products and services including LIMITX Technology and AVERSION Technology. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas. Its legal entity is Acura Pharmaceuticals, Inc.
Company details
Acura Pharm was founded in 1935 and is based in Palatine, United States. Operations in the pharmaceutical sector involve research, development, and commercialization of abuse-deterrent drug delivery technologies. Proprietary platforms are licensed to other companies for product applications. These technologies are engineered to reduce overdose risks, prevent tampering methods like snorting or injection, and limit pseudoephedrine extraction for illicit uses such as methamphetamine production.
- Headquarters Palatine, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website acurapharm.com
- Social LinkedIn
- Legal Name Acura Pharmaceuticals, Inc.
- Annual Revenue$1.56 M (USD)-56.22as on Dec 31, 2021
- Net Profit-$879 K (USD)27.24as on Dec 31, 2021
- EBITDA-$1.08 M (USD)-3177.14as on Dec 31, 2021
- Latest Funding Round$1.8M (USD), Debt – Conventional
Oct 2018
- InvestorsHHS
& 1 more
Products & Services of Acura Pharm
Acura Pharm offers a comprehensive portfolio of products and services, including LIMITX Technology and AVERSION Technology.
LIMITX Technology is used to minimize overdose risks by retarding the release of active ingredients when excessive tablets are ingested.
AVERSION Technology is applied to incorporate barriers that discourage tampering and abuse through methods like injection or snorting.
Funding Insights of Acura Pharm
- Total Rounds 4
- Last Round Debt – Conventional β $1.8M
- First Round $300,000
(Aug 2014)
- Investors Count 2
All 4 funding rounds of Acura Pharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $1.8M | Debt – Conventional | β | β | |
| Jul 2017 | $4M | Post-IPO | β | β | β |
| Sep 2014 | $299,694 | Grant | β | β | |
| Aug 2014 | $300,000 | Grant | β | β | β |
2 investors in total: 1 institutional and 1 angel.
Investors in Acura Pharm
Acura Pharm has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include HHS and John Schutte.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
JS John Schutte | unknown_aa49cba2ea6a49a6b |
Investor details for Acura Pharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Acura Pharm
Acura Pharm is a publicly listed company on the OTC with ticker symbol ACUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Mar 1992
- Listed onOTCMKTS: ACUR
- Listed entityAcura Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS00509L8028
- Share price$0.00 · 2026-10-06
- Market capitalisation$6,666.18
- Volume (last session)34,348
Financials of Acura Pharm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2021 | $1.6M | -$879,000 | -$1.1M |
| 2020 | $3.6M | -$1.2M | $35,000 |
Detailed financial statements for Acura Pharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Acura Pharm
4 dated milestones of Acura Pharm across 83 years, from founding to its latest funding, stage changes and deals.
- Founded Acura Pharm is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $300K.
- Funding Latest funding round, Debt β Conventional, of $1.8M.
Web traffic of Acura Pharm
The website of Acura Pharm (acurapharm.com) receives about 2.4K visits a month and ranks #8,922,263 among all websites worldwide, #7,537 in Biotechnology and Pharmaceuticals.
- Monthly visits2.4K
▲ 43% vs previous month
- Global rank#8,922,263
among all websites
- Category rank#7,537
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit10 sec
- DevicesDesktop 40% Β· Mobile 60%
Websites whose visitors overlap most with Acura Pharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| risingpharma.com | 100% | 5.1K | #2,708,467 | View details | |
| amneal.com | 98% | 26.8K | #959,075 | View details | |
west-ward.com | west-ward.com | 98% | β | ||
| clementiapharma.com | 96% | View details | |||
| purduepharma.com | 95% | 26.1K | #875,078 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 12 similar websites and full traffic analytics for Acura Pharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Acura Pharm (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acura Pharm
Complete news archive for Acura Pharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acura Pharm
Acura Pharm was founded in 1935 and raised its 1st funding round 79 years after it was founded.
Acura Pharm is headquartered in Palatine, United States. It is registered at Palatine, Illinois, United States.
Annual revenue of Acura Pharm is $1.56M as on Dec 31, 2021.
Acura Pharm was founded in 1935 and is based in Palatine, United States. Operations in the pharmaceutical sector involve research, development, and commercialization of abuse-deterrent drug delivery technologies. Proprietary platforms are licensed to other companies for product applications. These technologies are engineered to reduce overdose risks, prevent tampering methods like snorting or injection, and limit pseudoephedrine extraction for illicit uses such as methamphetamine production.
Acura Pharm offers LIMITX Technology and AVERSION Technology.
Yes, Acura Pharm is publicly traded on OTC under the ticker symbol ACUR.
Acura Pharm has 2 investors. Key investors include HHS, and John Schutte.
Acura Pharm operates through Acura Pharmaceuticals, Inc.
